Nyra Medical Company Research Report

Company Overview

• Name: Nyra Medical

• Mission: Nyra Medical is focused on developing a novel therapy for mitral regurgitation.

• Founded: No information is available.

• Founder: Murali Padala, PhD

• Key People:

• Lori Chmura, Chief Executive Officer

• Murali Padala, PhD, Founder & Chief Scientific Officer

• Adam Martinez, PhD, Vice President of Product Development

• Hector Collazo Melendez, R&D Engineer

• Kirthana Suresh, PhD, Product Development Engineer

• Nathan Bennett, Principal R&D Engineer

• Nancy Ness, Chief Financial Officer

• Alvin Laohapant, Sr R&D Engineer

• Steffanie Yeung, R&D Engineer

• Board of Directors:

• Amrinder Singh, Vensana Capital, Director

• Lisa Wipperman Heine, Independent, Director

• Murali Padala, PhD, Founder, Director

• Justin Klein, MD, JD, Vensana Capital, Observer

• Terri Burke, Epidarex Capital, Observer

• Lori Chmura, CEO, Director

• Daniel Gottlieb, Broadview Ventures, Observer

• Eric Sarin, MD, Observer

• Headquarters: No information is available.

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Nyra Medical is known for its focus on developing novel therapy for mitral regurgitation.

Products

Cardiac Leaflet Enhancer (CARLEN)

• Description: CARLEN is a transcatheter technology designed to modify the native mitral valve leaflets with a proprietary implant. Its aim is to correct deficiencies that lead to mitral regurgitation while preserving the physiological valve geometry.

• Key Features:

• Modifies mitral valve leaflets to correct deficiencies.

• Preserves the physiological valve geometry.

• Targets the correction of mitral regurgitation across different valve anatomies.

• Preserves the option for future transcatheter and surgical treatments.

Note: Nyra Medical's products are investigational devices and are not meant for sale or use in any geography at this time.

Recent Developments

• 2021: Nyra Medical obtained an exclusive license to the transcatheter CARLEN technology from Emory University.

• Nov 2022: Nyra Medical raised $20 million in Series A funding for its transcatheter heart valve repair technology.

• Aug 2023: Lori Chmura was appointed as CEO of Nyra Medical.

No further information on recent product launches, new features, or partnerships is available.

Mitral Regurgitation

• Clinical Need: Functional or secondary mitral regurgitation (FMR/SMR) is a heart valve lesion diagnosed in nearly 50% of patients surviving with atrial or ventricular cardiomyopathies. It significantly increases mortality and hospitalization rates in heart failure patients, impacting their quality of life.

Nyra Medical emphasizes the significant survival benefits, reduced heart failure hospitalizations, and improved quality of life that can result from effectively and timely treating FMR.

Safety Information: The Cardiac Leaflet Enhancer (CARLEN) Implant is MR Conditional with specific static magnetic field and SAR requirements.

Conclusion

Nyra Medical is highly concentrated on advancing the treatment of mitral regurgitation with its investigational product, CARLEN. While still in the developmental phase, Nyra has secured significant funding and leadership to drive its mission forward. The company remains poised to make substantial contributions to medical technology related to heart valve deficiencies. However, many operational specifics and future developments remain under wraps as products are still investigational and not available on the market.